Lung Cancer Trial Finds Higher Disease-Free Survival Rate With ALK Inhibitor Ensartinib, Study Shows

The New England Journal of Medicine has published results from the ELEVATE trial, showing ensartinib improved two-year disease-free survival in patients with resected ALK-positive non-small-cell lung cancer compared to placebo.

—

What the ELEVATE Trial Found

The New England Journal of Medicine has posted findings from the ELEVATE trial, a clinical study examining the use of ensartinib — an ALK inhibitor — in patients who had already undergone surgery to remove ALK-positive non-small-cell lung cancer. According to the post from the journal’s official X account, two-year disease-free survival was higher among patients receiving ensartinib than among those given a placebo.

That’s a meaningful distinction. Disease-free survival measures the length of time after treatment during which a patient shows no signs of the cancer returning — and in lung cancer care, it’s one of the key benchmarks clinicians watch closely after surgery.

The Trade-Off: Side Effects

The trial results weren’t straightforwardly positive across the board. According to the journal’s post, grade 3 adverse events — meaning serious side effects that require medical intervention but are not immediately life-threatening — were more frequent in patients taking ensartinib than in those receiving placebo. The post does not specify the exact rate of those adverse events, and full details are available in the published trial paper.

ALK-positive non-small-cell lung cancer is a specific subtype of lung cancer driven by a genetic alteration in the ALK gene. It tends to affect a younger patient population than many other lung cancer subtypes and accounts for a relatively small proportion of all lung cancer diagnoses, according to existing clinical literature. Ensartinib belongs to a class of targeted drugs designed to block the activity of the abnormal ALK protein that drives tumour growth.

Understanding the Science

Non-small-cell lung cancer is the most common form of lung cancer overall, making up the large majority of diagnoses. Within that group, ALK-positive cases are identified through genetic testing of tumour tissue. Targeted therapies like ensartinib work differently from traditional chemotherapy — rather than attacking all rapidly dividing cells, they aim to interfere with a specific molecular pathway that the cancer depends on.

The ELEVATE trial specifically focused on patients who had already had surgery to remove their tumour, a setting known clinically as the adjuvant or post-resection setting. Using targeted therapy after surgery to reduce the risk of cancer returning is an active area of research across multiple cancer types.

What Comes Next

The full trial results are published in the New England Journal of Medicine. Questions that remain include the longer-term survival outcomes beyond two years, the precise rates of serious adverse events in each group, and how ensartinib compares to other ALK inhibitors already used in the adjuvant setting. It’s also unclear at this stage how quickly findings of this kind might influence prescribing guidelines in the UK, where NICE — the National Institute for Health and Care Excellence — evaluates new treatments before they are routinely commissioned on the NHS.

—

Key Takeaways

• The ELEVATE trial found that two-year disease-free survival was higher with ensartinib than with placebo in patients with resected ALK-positive non-small-cell lung cancer, according to the New England Journal of Medicine
• Grade 3 adverse events — serious side effects requiring medical attention — were more frequent in the ensartinib group than in the placebo group
• Full results are published in the New England Journal of Medicine; longer-term survival data and the drug’s path to routine NHS use remain to be established

—

What This Means for Kent Residents

Patients in Kent who have been diagnosed with lung cancer, or who have a family history of the disease, should speak to their GP or hospital specialist about whether genetic testing for ALK-positive status is appropriate in their case — this kind of molecular testing is what determines eligibility for targeted therapies like ensartinib. NHS Kent and Medway covers cancer services across the county, and any questions about new or emerging treatments are best directed to a named oncology consultant or via NHS 111 if you’re unsure where to start. For general concerns about lung health, breathing symptoms, or unexplained weight loss — all potential warning signs that the NHS advises taking seriously — contact your GP in the first instance, or call NHS 111 for guidance; in an emergency, always call 999.